[O:1]=[S:2]1(=[O:20])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[C:9]([S:16]([CH3:19])(=[O:18])=[O:17])[CH:8]=1.Cl.[CH:22]1([C:25]2[C:26]([N:34]3[CH2:39][CH2:38][NH:37][CH2:36][CH2:35]3)=[N:27][CH:28]=[C:29]([CH:31]3[CH2:33][CH2:32]3)[CH:30]=2)[CH2:24][CH2:23]1>>[CH:22]1([C:25]2[C:26]([N:34]3[CH2:35][CH2:36][N:37]([C:11]([C:10]4[CH:14]=[CH:15][C:7]([N:3]5[CH2:4][CH2:5][CH2:6][S:2]5(=[O:1])=[O:20])=[CH:8][C:9]=4[S:16]([CH3:19])(=[O:18])=[O:17])=[O:13])[CH2:38][CH2:39]3)=[N:27][CH:28]=[C:29]([CH:31]3[CH2:33][CH2:32]3)[CH:30]=2)[CH2:23][CH2:24]1Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methanesulfonylbenzoic acid (319 mg) described in Preparation Example 22 and 1-(3,5-dicyclopropylpyridin-2-yl)piperazine hydrochloride (280 mg) described in Preparation Example 87 and by the reaction and treatment in the same manner as in Example 86, the title compound (427 mg) was obtained.